Digestive Diseases
| Ulcerative colitis
Digestive Diseases
Ulcerative colitis
TRIUMPH: Tofacitinib in patients hospitalized with ASUC
book_2
Source:
ECCO 2024 - Oral session
calendar_today
Published on Medfyle:
March 2024
import_contacts
7
min
headphones
4
min
In this medfyle
ASUC affects up to 25% of people with UC, and time to response is critical. Current treatment options are limited, but there could be a place for tofacitinib. New data from TRIUMPH explore clinical response, with favorable results.
Expert commentary
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Medfyle. All rights reserved.
Source: Narula N, Peerani F, Hansen T, et al. DOP46 Tofacitinib for hospitalized acute severe Ulcerative Colitis – the TRIUMPH study. J Crohns Colitis 2024;18(suppl1):jjad212.0086 [DOP46]
The information and data provided is for information purposes only.
The author(s) of the original article had no involvement in the creation of this content.
